Drugs in ATC Class L01XK

Up to Top Level ATC Classes

Up to L - Antineoplastic and immunomodulating agents

Up to L01 - ANTINEOPLASTIC AGENTS

Up to L01X - OTHER ANTINEOPLASTIC AGENTS

Drugs in ATC Class: L01XK - Poly (ADP-ribose) polymerase (PARP) inhibitors

Tradename	Generic Name
LYNPARZA	olaparib
AKEEGA	abiraterone acetate; niraparib tosylate
ZEJULA	niraparib tosylate

ATC Class L01XK: PARP inhibitors. Market dynamics and patent landscape

Last updated: April 24, 2026

What does L01XK cover, and how has the market scaled?

ATC class L01XK is the oncology small-molecule class of poly (ADP-ribose) polymerase (PARP) inhibitors used across DNA-damage response settings, including BRCA-mutated and broader HRD (homologous recombination deficiency) populations.

Core marketed PARP inhibitors (typical ATC inclusion)

The class in practice centers on: olaparib, niraparib, rucaparib, talazoparib, and veliparib; plus combination regimens using these agents as backbones. (ATC classification is maintained by WHO Collaborating Centre for Drug Statistics Methodology.) [1]

Key market dynamics shaping L01XK

1) Indication expansion is the main unit-of-sale driver.
Early uptake in BRCA-mutant disease expanded into HRD biomarker-defined groups and later broader lines in ovarian cancer, prostate cancer, and breast cancer. That expansion changed the commercial profile from “niche genetic oncology” to “biomarker-defined standards of care.”

2) Competitive differentiation shifted from potency to durability and tolerability.
Mechanism is shared, so commercial outcomes increasingly track:

• dosing schedules and adherence profile
• hematologic tolerability management (especially anemia and thrombocytopenia)
• real-world persistence and dose modifications

3) Combination therapy is now structurally dominant in pipeline value.
PARP inhibitors are increasingly paired with:

• DNA damage agents (eg, chemotherapy)
• anti-angiogenics
• immuno-oncology approaches
• targeted agents aligned with resistance pathways

4) Resistance management is a patent battleground.
Resistance is typically driven by restoration of HR (eg, BRCA reversion, loss of 53BP1 pathway changes) and PARP1 alterations. Patents increasingly cluster around:

• next-generation compounds with different binding kinetics or selectivity
• resistance-combination strategies
• patient selection and treatment scheduling
• use of biomarkers tied to response/resistance

Who dominates L01XK revenue today (and what does that imply for patent value)?

The market is concentrated around a small set of “platform” PARP inhibitors. Patent value is tied to two things: 1) whether the molecule remains in first-line or moves into earlier lines (longer runway) 2) whether combinations and new indications create non-overlapping exclusivity layers (data exclusivity, pediatric extensions, formulation patents)

Practical implication for patent analytics: for L01XK, the most defensible IP is rarely a single composition patent alone. Value often sits in:

• second-generation salts/polymorphs
• dosing regimens
• combination claims
• biomarker-selected use claims
• manufacturing/process claims
• method-of-treatment and method-of-dosing claims that remain enforceable even after composition expiry

How does the patent landscape look by protection layer?

PARP inhibitor IP typically breaks into overlapping layers that extend economic life.

1) Composition-of-matter (primary molecule patents)

These cover the active pharmaceutical ingredient structure (the “core” claims). They set the outer edge for generic entry on composition.

2) Solid state (polymorph/salt/hydrate) and formulation patents

For PARP inhibitors, formulation IP is a key extension route. Common subtypes:

• specific polymorphs
• solvates/hydrates
• controlled-release or modified-release formulations (when applicable)
• particular granulation and tablet/film-coating specs

3) Method-of-use and combination patents

These often provide:

• new indications
• new patient-selection strategies
• new combinations with other approved anticancer agents
• dosing schedules and sequencing (eg, concomitant versus sequential)

4) Process and manufacturing patents

These cover:

• synthetic routes
• intermediates
• purification steps
• scale-up improvements that may still be patent-protected

5) Regulatory exclusivity (non-patent)

Regulatory exclusivity is not a patent, but it affects entry timing and patent enforcement leverage.

What are the main patent clusters for PARP inhibitors?

The modern L01XK landscape is structured around four major competitive strategies.

Cluster A: Next-generation PARP inhibitors

These attempt to extend market life by improving:

• PARP trapping potency
• PARP1/2 selectivity profiles
• CNS penetration (for subsets of indications)
• resistance handling via binding or downstream effect changes

Cluster B: “PARP inhibitor +” combinations

This is the dominant cluster for post-approval differentiation because it creates multiple potential claim vectors:

• synergy-based combinations
• dosing windows
• maintenance strategies
• biomarker-enrichment combinations

Cluster C: Resistance biomarker IP

Expect claims around:

• BRCA1/2 mutation status
• HRD scores and genomic scars
• markers of PARP trapping and DNA damage response
• proof that specific biomarker strata benefit from PARP inhibition

Cluster D: Improved dosing regimens

Claims around:

• dose escalation or reduction protocols
• schedule optimization (intermittent versus continuous)
• management-of-toxicity adjustments for specific lab thresholds

Which legal and commercial “pressure points” affect enforcement?

Three practical forces compress time windows for challengers and determine the credible duration of IP.

1) Multi-jurisdiction filings with staggered priority dates.
PARP inhibitor portfolios are usually filed globally. Enforcement value depends on which jurisdictions maintain the most durable claim sets after examination and opposition.

2) Claim narrowing during prosecution and patent family heterogeneity.
A single molecule family often contains multiple claim sets that survive in some countries but narrow in others. That makes watch-listing per jurisdiction essential.

3) Generic and biosimilar-like entry logic for small molecules (ANDA-style).
When composition patents narrow or expire, generics can still enter quickly unless formulation or method-of-use claims block entry in specific countries.

Market strategy implications for investors and R&D

For L01XK, the highest-value questions are not “is the drug active,” but:

• whether new claims create enforceable barriers during commercial peak
• whether combination IP overlaps with the standard-of-care backbone in major indications
• whether resistance biomarker claims remain supported by trial designs and subgroup analyses

From a business perspective, PARP inhibitors are now an “ecosystem” market:

• mainline products are mature
• incremental pipeline value concentrates on combinations and next-generation efficacy against resistance

Patent landscape: how to map families to freedom-to-operate risk

A defensible patent-to-FTO workflow for L01XK uses a layered approach:

Step 1: Anchor on the active ingredient families

For each PARP inhibitor marketed under ATC L01XK, map:

• composition-of-matter families
• key process families
• key solid-state/formulation families

Step 2: Layer in jurisdictional survival

Track for each family:

• grant status
• claim scope after prosecution
• expiry dates (earliest and latest)
• patent linkage to specific formulation strengths and dosage forms

Step 3: Identify “secondary” blockers

Method-of-use and combination patents typically survive as the most active blockers:

• the regimen (dose, schedule)
• combination partner
• indication
• biomarker stratification

Step 4: Stress-test around standard care

If a regimen becomes standard-of-care in an indication, combination patents can block not only the molecule sale but also labeling or treatment protocols tied to those claims.

Timeline mechanics: why expiry pacing matters more than single-date snapshots

PARP inhibitor portfolios often have:

• multiple overlapping patents with different priority dates
• regulatory extensions or pediatric extensions in some jurisdictions
• family splits (continuations and divisional strategies)

In practice, that means a “molecule expiry date” is rarely the limiting factor. The limiting factor is which specific claim set blocks generic entry in a given jurisdiction for a given dosage form.

Competitive landscape by strategy (IP posture)

The patent posture across companies in L01XK typically aligns with:

• Originator full-stack portfolios: composition + formulation + method-of-use for core indications and maintenance strategies.
• Next-generation incumbents: “new compound” families plus combination testing to create a parallel claim ecosystem.
• Combination specialists: method-of-use claims with partner therapies and regimen-specific dosing claims.
• Process innovators: process and intermediate patents that are narrower but can delay ANDA readiness and supply-chain changes.

What does the ATC assignment imply for patent searches?

ATC L01XK is a classification tool, not a patent category. It is still useful for scoping because it defines the clinical mechanism class you need to cover in:

• method-of-treatment claim review
• combination use claim review
• biomarker-restricted use claim review
• regimen-specific claims for PARP inhibitor dosing schedules

Key takeaways for L01XK patent strategy

1) The highest-value IP is layered. Composition claims define an outer boundary, but formulation, dosing regimen, and combination method-of-use claims often define the enforceable runway.
2) Combination and biomarker claims drive post-maturity differentiation. As standard-of-care expands, enforceable claims increasingly track clinical regimens and patient selection.
3) Jurisdiction-specific survival matters. Family heterogeneity means expiration is not uniform; enforcement leverage depends on claim sets that remain in force per country.
4) Resistance biology creates repeat filing opportunities. Resistance pathway claims (and the required patient stratification) keep method-of-use and biomarker portfolios active even as composition patents approach expiry.

FAQs

1) What does ATC class L01XK include?
It is the WHO ATC category for PARP inhibitors used in oncology, anchored on drugs like olaparib, niraparib, rucaparib, talazoparib, and veliparib and related PARP inhibitor products. [1]

2) Why do patent strategies in PARP inhibitors extend beyond composition-of-matter?
Because generics can enter once composition claims expire unless formulation, solid-state, dosing regimen, or method-of-use claims still block sale or treatment protocols tied to the claimed regimens.

3) What is the most important driver of L01XK commercial growth now?
Indication expansion and uptake of PARP inhibitor combinations and maintenance strategies, which create new method-of-use claim targets.

4) How does resistance affect the patent landscape?
Resistance mechanisms support claims around specific biomarker strata, combination approaches, and treatment sequencing, which creates new enforceable angles even after core efficacy is established.

5) What is the biggest FTO risk pattern for PARP inhibitor generics?
Ignoring method-of-use and regimen-specific combination claims that can block practical entry even when composition-of-matter patents are near expiry or expired.

---

References

[1] World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC classification index: L01XK (Poly(ADP-ribose) polymerase (PARP) inhibitors). WHO. https://www.whocc.no/ (accessed 2026-04-25).